1887

Abstract

A comprehensive meningococcal vaccine is yet to be developed. In the absence of a vaccine that immunizes against the serogroup B capsular polysaccharide, this can only be achieved by targeting subcapsular antigens, and a number of outer-membrane proteins (OMPs) are under consideration as candidates. A major obstacle to the development of such a vaccine is the antigenic diversity of these OMPs, and obtaining population data that accurately identify and catalogue these variants is an important component of vaccine design. The recently proposed meningococcal molecular strain-typing scheme indexes the diversity of two OMPs, PorA and FetA, that are vaccine candidates, as well as the capsule and multilocus sequence type. This scheme was employed to survey 323 meningococci isolated from invasive disease in England and Wales from 1975 to 1995, before the introduction of meningococcal conjugated serogroup C polysaccharide vaccines in 1999. The eight-locus typing scheme provided high typeability (99.4 %) and discrimination (Simpson's diversity index 0.94–0.99). The data showed cycling of meningococcal genotypes and antigenic types in the absence of planned interventions. Notwithstanding high genetic and antigenic diversity, most of the isolates belonged to one of seven clonal complexes, with 11 predominant strain types. Combinations of PorA and FetA, chosen on the basis of their prevalence over time, generated vaccine recipes that included protein variants found in 80 % or more of the disease isolates for this time period. If adequate immune responses can be generated, these results suggest that control of meningococcal disease with relatively simple protein component vaccines may be possible.

Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.2007/014761-0
2008-04-01
2020-08-09
Loading full text...

Full text loading...

/deliver/fulltext/micro/154/4/1170.html?itemId=/content/journal/micro/10.1099/mic.0.2007/014761-0&mimeType=html&fmt=ahah

References

  1. Achtman M.. 1997; Microevolution and epidemic spread of serogroup A Neisseria meningitidis – a review. Gene192:135–140
    [Google Scholar]
  2. Bjune G., Høiby E. A., Grønnesby J. K., Arnesen O., Fredriksen J. H., Halstensen A., Holten E., Lindbak A. K., Nøkleby H.. other authors 1991; Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338:1093–1096
    [Google Scholar]
  3. Brehony C., Jolley K. A., Maiden M. C.. 2007; Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev31:15–26
    [Google Scholar]
  4. Bygraves J. A., Urwin R., Fox A. J., Gray S. J., Russell J. E., Feavers I. M., Maiden M. C. J.. 1999; Population genetic and evolutionary approaches to the analysis of Neisseria meningitidis isolates belonging to the ET-5 complex. J Bacteriol181:5551–5556
    [Google Scholar]
  5. Caugant D. A.. 1998; Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS106:505–525
    [Google Scholar]
  6. Caugant D. A.. 2001; Global trends in meningococcal disease. . In Meningococcal Disease: Methods and Protocols pp273–294 Edited by Pollard A. J., Maiden M. C. J.. Totowa, NJ: Humana Press;
  7. Elias J., Harmsen D., Claus H., Hellenbrand W., Frosch M., Vogel U.. 2006; Spatiotemporal analysis of invasive meningococcal disease, Germany. Emerg Infect Dis12:1689–1695
    [Google Scholar]
  8. Feavers I. M., Gray S. J., Urwin R., Russell J. E., Bygraves J. A., Kaczmarski E. B., Maiden M. C. J.. 1999; Multilocus sequence typing and antigen gene sequencing in the investigation of a meningococcal disease outbreak. J Clin Microbiol37:3883–3887
    [Google Scholar]
  9. Finne J., Leinonen M., Makela P. H.. 1983; Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet2:355–357
    [Google Scholar]
  10. Gold R., Lepow M. L., Goldschneider I., Draper T. F., Gotshlich E. C.. 1979; Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis140:690–697
    [Google Scholar]
  11. Gupta S., Maiden M. C. J.. 2001; Exploring the evolution of diversity in pathogen populations. Trends Microbiol9:181–185
    [Google Scholar]
  12. Gupta S., Maiden M. C. J., Feavers I. M., Nee S., May R. M., Anderson R. M.. 1996; The maintenance of strain structure in populations of recombining infectious agents. Nat Med2:437–442
    [Google Scholar]
  13. Harrison L. H., Jolley K. A., Shutt K. A., Marsh J. W., O'Leary M., Sanza L. T., Maiden M. C.. 2006; Antigenic shift and increased incidence of meningococcal disease. J Infect Dis193:1266–1274
    [Google Scholar]
  14. Hunter P. R., Gaston M. A.. 1988; Numerical index of discriminatory ability of typing systems: an application of Simpson's index of diversity. J Clin Microbiol26:2465–2466
    [Google Scholar]
  15. Jodar L., Feavers I. M., Salisbury D., Granoff D. M.. 2002; Development of vaccines against meningococcal disease. Lancet359:1499–1508
    [Google Scholar]
  16. Jolley K. A., Maiden M. C.. 2006; AgdbNet – antigen sequence database software for bacterial typing. BMC Bioinformatics7:314
    [Google Scholar]
  17. Jolley K. A., Kalmusova J., Feil E. J., Gupta S., Musilek M., Kriz P., Maiden M. C.. 2000; Carried meningococci in the Czech Republic: a diverse recombining population. J Clin Microbiol38:4492–4498
    [Google Scholar]
  18. Jolley K. A., Chan M. S., Maiden M. C.. 2004; mlstdbNet – distributed multi-locus sequence typing (MLST) databases. BMC Bioinformatics5:86
    [Google Scholar]
  19. Jolley K. A., Brehony C., Maiden M. C.. 2007; Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev31:89–96
    [Google Scholar]
  20. Jones D. M., Sutcliffe E. M.. 1990; Group A meningococcal disease in England associated with the Haj. J Infect21:21–25
    [Google Scholar]
  21. Maiden M. C.. 2002; Population structure of Neisseria meningitidis. In Emerging Strategies in the Fight Against Meningitis: Molecular and Cellular Aspects pp151–170 Edited by Ferreirós C., Criado M. T., Vázquez J.. Wymondham, Norfolk: Horizon Scientific Press;
    [Google Scholar]
  22. Maiden M. C.. 2004; Dynamics of bacterial carriage and disease: lessons from the meningococcus. Adv Exp Med Biol549:23–29
    [Google Scholar]
  23. Maiden M. C. J., Bygraves J. A., Feil E., Morelli G., Russell J. E., Urwin R., Zhang Q., Zhou J., Zurth K.. & other authors 1998; Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A95:3140–3145
    [Google Scholar]
  24. Miller E., Salisbury D., Ramsay M.. 2001; Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20:Suppl. 1S58–S67
    [Google Scholar]
  25. O'Hallahan J., Lennon D., Oster P.. 2004; The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr Infect Dis J23:S293–S298
    [Google Scholar]
  26. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D.. 2005; MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine23:2191–2196
    [Google Scholar]
  27. Perkins B. A., Jonsdottir K., Briem H., Griffiths E., Plikaytis B. D., Hoiby E. A., Rosenqvist E., Holst J., Nokleby H.. other authors 1998; Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis177:683–691
    [Google Scholar]
  28. Perrett K. P., Pollard A. J.. 2005; Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opin Biol Ther5:1611–1625
    [Google Scholar]
  29. Pizza M., Scarlato V., Masignani V., Giuliani M. M., Arico B., Comanducci M., Jennings G. T., Baldi L., Bartolini E.. other authors 2000; Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science287:1816–1820
    [Google Scholar]
  30. Russell J. E., Jolley K. A., Feavers I. M., Maiden M. C., Suker J. S.. 2004; PorA variable regions of Neisseria meningitidis. Emerg Infect Dis10:674–678
    [Google Scholar]
  31. Sacchi C. T., Whitney A. M., Popovic T., Beall D. S., Reeves M. W., Plikaytis B. D., Rosenstein N. E., Perkins B. A., Tondella M. L.. other authors 2000; Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992–1998. J Infect Dis182:1169–1176
    [Google Scholar]
  32. Sierra G. V. G., Campa H. C., Varcacel N. M., Garcia I. L., Izquierdo P. L., Sotolongo P. F., Casanueva G. V., Rico C. O., Rodriguez C. R.. other authors 1991; Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann14:195–207
    [Google Scholar]
  33. Simpson E. H.. 1949; Measurement of diversity. Nature163:688
    [Google Scholar]
  34. Staden R.. 1996; The Staden sequence analysis package. Mol Biotechnol5:233–241
    [Google Scholar]
  35. Stein D. M., Robbins J., Miller M. A., Lin F. Y., Schneerson R.. 2006; Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?. Vaccine24:221–228
    [Google Scholar]
  36. Stephens D. S.. 2007; Conquering the meningococcus. FEMS Microbiol Rev31:3–14
    [Google Scholar]
  37. Suker J., Feavers I. M., Achtman M., Morelli G., Wang J.-F., Maiden M. C. J.. 1994; The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation. Mol Microbiol12:253–265
    [Google Scholar]
  38. Swaminathan B., Matar G. M., Reeves M. W., Graves L. M., Ajello G., Bibb W. F., Helsel L. O., Morales M., Dronavalli H.. other authors 1996; Molecular subtyping of Neisseria meningitidis serogroup B: comparison of five methods. J Clin Microbiol34:1468–1473
    [Google Scholar]
  39. Swartley J. S., Marfin A. A., Edupuganti S., Liu L. J., Cieslak P., Perkins B., Wenger J. D., Stephens D. S.. 1997; Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci U S A94:271–276
    [Google Scholar]
  40. Taha M. K., Alonso J. M., Cafferkey M., Caugant D. A., Clarke S. C., Diggle M. A., Fox A., Frosch M., Gray S. J.. other authors 2005; Interlaboratory comparison of PCR-based identification and genogrouping of Neisseria meningitidis. J Clin Microbiol43:144–149
    [Google Scholar]
  41. Thompson E. A. L., Feavers I. M., Maiden M. C. J.. 2003; Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology149:1849–1858
    [Google Scholar]
  42. Trotter C. L., Chandra M., Cano R., Larrauri A., Ramsay M. E., Brehony C., Jolley K. A., Maiden M. C., Heuberger S.. other authors 2007; A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev31:27–36
    [Google Scholar]
  43. Urwin R., Russell J. E., Thompson E. A., Holmes E. C., Feavers I. M., Maiden M. C.. 2004; Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun72:5955–5962
    [Google Scholar]
  44. van den Dobbelsteen G. P. J. M., van Dijken H. H., Pillai S., van Alphen L.. 2007; Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine25:2491–2496
    [Google Scholar]
  45. Vogel U., Claus H., Frosch M.. 2000; Rapid serogroup switching in Neisseria meningitidis. N Engl J Med342:219–220
    [Google Scholar]
  46. Yazdankhah S. P., Kriz P., Tzanakaki G., Kremastinou J., Kalmusova J., Musilek M., Alvestad T., Jolley K. A., Wilson D. J.. other authors 2004; Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol42:5146–5153
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.2007/014761-0
Loading
/content/journal/micro/10.1099/mic.0.2007/014761-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error